Andreas Viardot

Albert Einstein Allee 23
Ulm, BW 89081, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 93 publications

Polatuzumab Vedotin Plus Rituximab, Gemcitabine, and Oxaliplatin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Results From the Phase III, Randomized POLARGO Trial.

Polatuzumab Vedotin Plus Rituximab, Gemcitabine, and Oxaliplatin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Results From the Phase III, Randomized POLARGO Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: July 06, 2026

CD20 expression dynamics in adult B-cell acute lymphoblastic leukemia and impact on anti-CD20 treatment.

CD20 expression dynamics in adult B-cell acute lymphoblastic leukemia and impact on anti-CD20 treatment.

Journal: Journal of hematology & oncology

Published: March 31, 2026

Patient characteristics and treatment outcomes in marginal zone lymphoma: results of the prospective German MZL registry.

Patient characteristics and treatment outcomes in marginal zone lymphoma: results of the prospective German MZL registry.

Journal: Leukemia

Published: July 25, 2025

Final analysis of the GMALL-PH-01 trial: phase II study of standard chemotherapy in combination with dasatinib in first line treatment of Philadelphia chromosome positive acute lymphoblastic leukemia.

Final analysis of the GMALL-PH-01 trial: phase II study of standard chemotherapy in combination with dasatinib in first line treatment of Philadelphia chromosome positive acute lymphoblastic leukemia.

Journal: Leukemia & lymphoma

Published: February 08, 2025

Outcomes of bispecific antibody therapy after CAR T-cell failure in relapsed/refractory large B-cell lymphoma.

Outcomes of bispecific antibody therapy after CAR T-cell failure in relapsed/refractory large B-cell lymphoma.

Journal: Blood advances

Published: December 23, 2024

Chemotherapy-free combination of ibrutinib and obinutuzumab for untreated advanced follicular lymphoma: results of a phase II study from the German Lymphoma Alliance.

Chemotherapy-free combination of ibrutinib and obinutuzumab for untreated advanced follicular lymphoma: results of a phase II study from the German Lymphoma Alliance.

Journal: Haematologica

Published: December 17, 2024

Fertility in patients with advanced-stage classic Hodgkin lymphoma treated with BrECADD versus eBEACOPP: a secondary analysis of the multicentre, randomised, parallel, open-label, phase 3 HD21 trial.

Fertility in patients with advanced-stage classic Hodgkin lymphoma treated with BrECADD versus eBEACOPP: a secondary analysis of the multicentre, randomised, parallel, open-label, phase 3 HD21 trial.

Journal: The Lancet. Oncology

Published: November 08, 2024

Safety and efficacy of glofitamab for relapsed/refractory large B-cell lymphoma in a multinational real-world study.

Safety and efficacy of glofitamab for relapsed/refractory large B-cell lymphoma in a multinational real-world study.

Journal: Blood advances

Published: September 23, 2024

Long-Term Follow-Up of the Prospective Randomized AATT Study (Autologous or Allogeneic Transplantation in Patients With Peripheral T-Cell Lymphoma).

Long-Term Follow-Up of the Prospective Randomized AATT Study (Autologous or Allogeneic Transplantation in Patients With Peripheral T-Cell Lymphoma).

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: September 13, 2024

Author Correction: Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study.

Author Correction: Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study.

Journal: Nature medicine

Published: July 09, 2024

Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial.

Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial.

Journal: Lancet (London, England)

Published: June 06, 2024

Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study.

Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study.

Journal: Nature medicine

Published: January 12, 2024

Showing 1-12 of 93

Last Updated: 09/26/2026